Mizuho Cuts Athira Pharma (NASDAQ:LONA) Price Target to $15.00

Athira Pharma (NASDAQ:LONA) had its target price trimmed by Mizuho from $16.00 to $15.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Several other equities research analysts have also recently issued reports on the stock. Wall Street Zen raised shares of Athira Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Citizens Jmp dropped their target price on Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating on the stock in a report on Monday, August 17th. Piper Sandler started coverage on Athira Pharma in a research note on Wednesday, May 27th. They issued an “overweight” rating and a $20.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Athira Pharma in a research note on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Athira Pharma has a consensus rating of “Moderate Buy” and an average price target of $17.33.

Athira Pharma Stock Down 0.3%

Shares of NASDAQ:LONA opened at $7.68 on Wednesday. Athira Pharma has a fifty-two week low of $3.52 and a fifty-two week high of $14.21. The firm’s 50 day moving average price is $8.22 and its 200 day moving average price is $8.35. The stock has a market cap of $72.12 million, a price-to-earnings ratio of -1.82 and a beta of 2.04.

Athira Pharma (NASDAQ:LONA) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.20). On average, equities analysts anticipate that Athira Pharma will post -2.67 EPS for the current year.

Hedge Funds Weigh In On Athira Pharma

Hedge funds have recently modified their holdings of the business. Focus Partners Wealth acquired a new position in shares of Athira Pharma in the 3rd quarter valued at $35,000. Jane Street Group LLC acquired a new position in Athira Pharma in the fourth quarter valued at $100,000. Renaissance Technologies LLC increased its stake in Athira Pharma by 44.7% in the fourth quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock valued at $569,000 after purchasing an additional 23,223 shares during the period. Seven Fleet Capital Management LP purchased a new stake in shares of Athira Pharma in the fourth quarter valued at about $969,000. Finally, Millennium Management LLC purchased a new stake in shares of Athira Pharma in the fourth quarter valued at about $2,456,000. 57.12% of the stock is currently owned by hedge funds and other institutional investors.

About Athira Pharma

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.